Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies Sebastião Cezar Radominski, Mario Humberto Cardiel, Gustavo Citera, Annelise Goecke, Juan Jose Jaller, Andrea Barranjard Vannucci Lomonte, Pedro Miranda, Patricia Velez, Daniel Xibillé, Kenneth Kwok, Ricardo Rojo, Erika Gabriela García

Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies Ruben Burgos-Vargas, Mario Cardiel, Daniel Xibillèc), Cèc)sar Pacheco-Tena, Virginia Pascual-Ramos, Carlos Abud-Mendoza, Ehab Mahgoub, Mahboob Rahman, Haiyun Fan, Ricardo Rojo, Erika García, Karina Santana

Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries J.M. Reyes, M.V. Gutierrez, H. Madariaga, W. Otero, R. Guzman, J. Izquierdo, M. Abello, P. Velez, D. Castillo, D. Ponce de Leon, T. Lukic, L. Amador